title: Vascular endothelial growth factor attenuates status epilepticus-induced behavioral impairments in rats.
abstract: Vascular endothelial growth factor (VEGF) is a vascular growth factor more recently recognized as a neurotrophic factor (for review, see Storkebaum E, Lambrechts D, Carmeliet P. BioEssays 2004;26:943-54). We previously reported that endogenous VEGF protein is dramatically upregulated after pilocarpine-induced status epilepticus in the rat, and that intra-hippocampal infusions of recombinant human VEGF significantly protected against the loss of hippocampal CA1 neurons in this model (Nicoletti JN, Shah SK, McCloskey DP, et al. Neuroscience 2008;151:232-41). We hypothesized that we would see a preservation of cognitive and emotional functioning with VEGF treatment accompanying the neuroprotection previously observed in this paradigm. Using the Morris water maze to evaluate learning and memory, and the light-dark task to assess anxiety, we found a selective profile of preservation. Specifically, VEGF completely preserved normal anxiety functioning and partially but significantly protected learning and memory after status epilepticus. To determine whether the ability of VEGF to attenuate behavioral deficits was accompanied by sustained preservation of hippocampal neurons, we stereologically estimated CA1 pyramidal neuron densities 4 weeks after status epilepticus. At this time point, we found no significant difference in neuronal densities between VEGF- and control-treated status epilepticus animals, suggesting that VEGF could have protected hippocampal functioning independent of its neuroprotective effect.
authors.affiliation: Neuropsychology Doctoral Subprogram, Graduate Center, City University of New York, New York, NY 11367, USA.
authors.forename: Jamee N
authors.initials: JN
authors.lastname: Nicoletti
authors.forename: Janice
authors.initials: J
authors.lastname: Lenzer
authors.forename: Elisa A
authors.initials: EA
authors.lastname: Salerni
authors.forename: Sachin K
authors.initials: SK
authors.lastname: Shah
authors.forename: Ahmed
authors.initials: A
authors.lastname: Elkady
authors.forename: Sidra
authors.initials: S
authors.lastname: Khalid
authors.forename: Dean
authors.initials: D
authors.lastname: Quinteros
authors.forename: Francis
authors.initials: F
authors.lastname: Rotella
authors.forename: David
authors.initials: D
authors.lastname: Betancourth
authors.forename: Susan D
authors.initials: SD
authors.lastname: Croll
mesh_terms: D000221:Adaptation, Ocular / Q000187:drug effects; D000704:Analysis of Variance; D000818:Animals; D001526:Behavioral Symptoms / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D004195:Disease Models, Animal; D006624:Hippocampus / Q000473:pathology; D006801:Humans; D008124:Locomotion / Q000187:drug effects; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D010862:Pilocarpine; D017966:Pyramidal Cells / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use; D013226:Status Epilepticus / Q000139:chemically induced / Q000150:complications*; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D010862:Pilocarpine
references.citation: J Neurosci. 2003 Dec 17;23(37):11505-15
references.pmid: 14684854
references.citation: J Cereb Blood Flow Metab. 2005 Dec;25(12):1557-72
references.pmid: 15889042
references.citation: Epilepsy Behav. 2005 Dec;7 Suppl 3:S3-11
references.pmid: 16278099
references.citation: Epilepsy Res. 1997 Jan;26(2):363-71
references.pmid: 9095398
references.citation: Exp Neurol. 2007 Oct;207(2):329-49
references.pmid: 17714705
references.citation: Exp Neurol. 2009 Sep;219(1):284-97
references.pmid: 19500573
references.citation: Seizure. 2002 Jun;11(4):224-30
references.pmid: 12027568
references.citation: Learn Mem. 2006 Jan-Feb;13(1):18-26
references.pmid: 16418436
references.citation: Prog Brain Res. 2002;135:67-83
references.pmid: 12143371
references.citation: Exp Neurol. 1998 Feb;149(2):398-410
references.pmid: 9500963
references.citation: Bioessays. 2004 Sep;26(9):943-54
references.pmid: 15351965
references.citation: Anat Rec. 1991 Dec;231(4):482-97
references.pmid: 1793176
references.citation: Neuroscience. 2008 Jan 2;151(1):232-41
references.pmid: 18065154
references.citation: J R Soc Med. 1991 Aug;84(8):460-5
references.pmid: 1886113
references.citation: Brain Res Mol Brain Res. 1998 Mar 30;55(1):54-60
references.pmid: 9645960
references.citation: Neurosci Lett. 1999 Dec 10;276(3):157-60
references.pmid: 10612629
references.citation: J Nutr. 2000 Apr;130(4S Suppl):1043S-5S
references.pmid: 10736378
references.citation: Ann Neurol. 2002 May;51(5):641-4
references.pmid: 12112114
references.citation: Arch Dis Child. 1998 Jul;79(1):73-7
references.pmid: 9771258
references.citation: J Neurosci. 2005 Sep 28;25(39):8889-97
references.pmid: 16192378
references.citation: Neuroscience. 1999;93(4):1491-506
references.pmid: 10501474
references.citation: J Pharmacol Sci. 2006;100(5):433-42
references.pmid: 16799259
references.citation: Annu Rev Neurosci. 1992;15:353-75
references.pmid: 1575447
references.citation: Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
references.pmid: 4110397
references.citation: Brain. 2005 Jun;128(Pt 6):1344-57
references.pmid: 15758032
references.citation: J Neurosci. 2001 Jan 1;21(1):356-62
references.pmid: 11150353
references.citation: J Biol Chem. 2007 Jun 22;282(25):18100-18107
references.pmid: 17472959
references.citation: Peptides. 1986 Jan-Feb;7(1):155-9
references.pmid: 3520509
references.citation: Ann Neurol. 2003 Mar;53(3):413-6
references.pmid: 12601713
references.citation: Pharmacol Rep. 2006 Jan-Feb;58(1):75-82
references.pmid: 16531633
references.citation: Behav Brain Res. 2009 Aug 12;201(2):292-9
references.pmid: 19428647
references.citation: Nature. 1986 Feb 27-Mar 5;319(6056):774-6
references.pmid: 2869411